Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

por Nicolas Nagot, Mandisa Singata-Madliki, Amandine Cournil, Joyce Nalugya, Souleymane Tassembedo, Catherine Quillet, Melany W. Tonga, James Tumwine, Nicolas Meda, Chipepo Kankasa, Mwiya Mwiya, Paul Bangirana, Marianne Peries, Joanne Batting, Ingunn M. S. Engebretsen, Thorkild Tylleskär, Philippe Vande Perre, Grace Ndeezi, Jean-Pierre Molès
Publicado 2021